Testing for small intestine cancer typically involves a combination of imaging scans, specialized endoscopy, and tissue biopsy, often triggered by unexplained symptoms like iron deficiency anemia, abdominal pain, or unintentional weight loss. Unlike colon cancer, there’s no routine screening test for small bowel tumors, so diagnosis usually begins after something abnormal shows up in bloodwork or initial imaging.
What Usually Triggers Testing
Small intestine cancer is rare, accounting for a small fraction of all gastrointestinal cancers, and it doesn’t have a standard screening program. Most people end up being tested because of persistent, unexplained symptoms. Iron deficiency anemia is one of the most common early findings, sometimes requiring multiple blood transfusions before a cause is identified. Stool tests may reveal hidden (occult) blood, pointing to bleeding somewhere in the digestive tract.
Other red flags include chronic abdominal pain, unexplained weight loss, nausea, or episodes of bowel obstruction. When colonoscopy and upper endoscopy come back normal but symptoms persist, doctors start looking more closely at the small intestine, the roughly 20 feet of gut that sits between the stomach and colon and is notoriously difficult to reach with standard scopes.
Capsule Endoscopy: The Starting Point
Video capsule endoscopy has become a first-line tool for visualizing the small bowel. You swallow a pill-sized camera that takes thousands of images as it travels through your digestive tract over about eight hours. It’s painless, requires no sedation, and captures detailed views of the intestinal lining that other tests can miss.
The main limitation is that capsule endoscopy can only look. It can’t take tissue samples, so if it spots something suspicious, you’ll need a follow-up procedure. There’s also a small risk the capsule can get stuck, particularly in people with known narrowing of the intestine, Crohn’s disease, prior abdominal radiation, or previous small bowel surgery. In those cases, doctors may first use a dissolvable “patency capsule” to confirm the passage is clear. Capsule endoscopy is generally avoided during pregnancy due to a lack of safety data, and people with swallowing difficulties may need the capsule placed endoscopically to prevent it from entering the airway.
CT and MRI Enterography
CT enterography is a specialized scan designed specifically for the small bowel, offering much better visualization than a standard abdominal CT. Before the scan, you drink about 1.5 to 2 liters of a liquid contrast agent over 45 to 60 minutes to distend the intestine, making the bowel wall easier to evaluate. An intravenous contrast dye is also given to highlight blood flow to any abnormal tissue. The combination of distended bowel and contrast-enhanced imaging lets radiologists spot thickened walls, masses, and abnormalities in the surrounding tissue.
CT enterography has a reported sensitivity of 85% and specificity of 97% for detecting both cancerous and benign small bowel tumors. That means it catches most tumors and rarely flags something that isn’t there. Interpreting these scans requires careful “navigation” through every loop of bowel, which can take up to 15 minutes per patient and has a significant learning curve for radiologists.
MRI enterography is an alternative that avoids radiation exposure. It appears to be more sensitive than CT for detecting superficial mucosal lesions, the kind of early, surface-level changes that might otherwise be missed. MRI is often preferred for younger patients or anyone who needs repeated imaging over time.
Double-Balloon Enteroscopy for Biopsy
When imaging or capsule endoscopy finds something suspicious, a tissue sample is needed to confirm cancer. Double-balloon enteroscopy is the primary tool for reaching deep into the small intestine and taking a biopsy. The technique uses a long, thin endoscope (about 2 meters, or roughly 6.5 feet) fitted with two inflatable balloons that alternately grip and release the intestinal wall, allowing the scope to inch forward through the bowel’s many loops.
The procedure can be performed through the mouth (anterograde) to examine the upper small intestine, through the rectum (retrograde) for the lower portion, or both in combination to cover the entire length. In one study of 56 patients, the technique successfully identified the source of bleeding in 95% of cases, and tissue samples confirmed the endoscopic findings 93% of the time. Beyond diagnosis, the scope can also mark lesion locations precisely, which helps surgeons plan any subsequent operation.
PET/CT for Staging
Once small intestine cancer is confirmed, PET/CT scans help determine how far the disease has spread. This scan detects areas of high metabolic activity, a hallmark of cancer cells, throughout the entire body. Small bowel adenocarcinoma, the most common type, typically shows up as thickened intestinal wall with increased uptake of the radioactive tracer.
PET/CT is useful at multiple stages: initial diagnosis, evaluating how well treatment is working, and checking for recurrence afterward. It’s particularly valuable for small bowel lymphoma and gastrointestinal stromal tumors (GISTs) as well. High-grade lymphomas tend to show intense metabolic activity, making them easier to detect and monitor.
Blood Tests and Tumor Markers
No single blood test can diagnose small intestine cancer, but several lab findings play supporting roles. A complete blood count revealing iron deficiency anemia, especially without an obvious cause, is one of the most common initial clues. Low iron stores combined with hidden blood in the stool points to chronic bleeding somewhere in the GI tract.
For neuroendocrine tumors, which are one of the more common small bowel cancer types, a blood marker called chromogranin A is elevated in about 80% of cases. Its sensitivity ranges from 60% to 100% and specificity from 70% to 100%, depending on the tumor type, with the highest accuracy seen in serotonin-producing carcinoid tumors. Chromogranin A outperforms other markers like CEA and urine 5-HIAA for neuroendocrine detection, though it can also be elevated in non-cancerous conditions, so it’s never used in isolation.
Stool Tests Have Limited Utility
Fecal immunochemical testing (FIT), which detects blood in stool, is widely used to screen for colon cancer but has a much less clear role in small bowel disease. In a study of patients with unexplained GI bleeding, FIT was positive in only 38% to 46% of those who turned out to have significant small bowel lesions on capsule endoscopy. That means more than half of people with real small bowel problems had a negative stool test. FIT can support the case for further investigation, particularly when colonoscopy has already come back clean, but a negative result does not rule out small intestine cancer.
Blood-Based Genomic Profiling
Because most small bowel tumors sit in locations that are hard to reach with a scope, blood-based genomic testing (sometimes called liquid biopsy) has emerged as an alternative way to analyze the tumor’s DNA. A study of 265 patients with small bowel adenocarcinoma used a blood draw to profile circulating tumor DNA and identify genetic mutations that could guide treatment decisions. This approach is especially valuable when a tissue biopsy isn’t feasible or doesn’t yield enough material for full genetic analysis.
Liquid biopsy can also be repeated over time to track how the cancer responds to treatment, detecting new mutations linked to drug resistance as they emerge. While this technology is primarily used after a cancer diagnosis rather than for initial detection, it represents a growing part of the diagnostic toolkit for small bowel cancers.
The Typical Diagnostic Sequence
In practice, testing usually follows a stepwise pattern. Initial bloodwork reveals anemia or another abnormality. Standard upper endoscopy and colonoscopy are performed first and come back without a clear explanation. At that point, capsule endoscopy or CT enterography (or both) is ordered to visualize the small bowel. If a suspicious lesion is found, double-balloon enteroscopy provides the tissue biopsy needed for a definitive diagnosis. Finally, PET/CT and additional imaging establish the cancer’s stage and guide treatment planning.
The entire process can take weeks to months, partly because small intestine cancer is uncommon enough that it’s often not the first suspicion. If you’re dealing with persistent, unexplained GI symptoms, particularly iron deficiency anemia that keeps coming back after treatment, pushing for small bowel-specific testing can make a meaningful difference in how quickly a diagnosis is reached.